On October 12, 2022, the U.S. Food and Drug Administration (FDA) announced a shortage of a drug formulation of amphetamine mixed salts, commonly referred to by the brand name Adderall. Adderall is an FDA approved drug for the treatment of narcolepsy and attention deficit hyperactivity disorder (ADHD), including anger, anxiety, forgetfulness and trouble focusing. Read more.